Analysts expect Edap Tms SA (NASDAQ:EDAP – Get Rating) to record sales of $16.87 million for the current quarter, reports Zacks Investment Research. Two analysts have made earnings estimates for Edap Tms, with estimates ranging from $15.50 million to $18.23 million. Edap Tms recorded sales of $18.35 million in the same quarter last year, suggesting a negative growth rate of 8.1% year-over-year. The company is expected to release its next results on Tuesday, March 29.

On average, analysts expect Edap Tms to record annual sales of $52.26 million for the current year, with estimates ranging from $50.40 million to $54.11 million . For the next fiscal year, analysts expect the company to record sales of $62.92 million, with estimates ranging from $62.52 million to $63.32 million. Zacks sales averages are an average average based on a survey of research analysts who provide coverage for Edap Tms.

A number of brokerages have weighed in on EDAP recently. HC Wainwright lowered its price target on Edap Tms from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 19. Zacks Investment Research upgraded Edap Tms from a “sell” rating to a “hold” rating in a Thursday, January 20 research report. B. Riley lowered his price target on Edap Tms from $13.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, November 19. Finally, StockNews.com supported Edap Tms’ coverage in a Thursday, March 10 research report. They issued a “hold” rating for the company. Two analysts rated the stock with a hold rating and three gave the company’s stock a buy rating. Based on MarketBeat data, Edap Tms currently has an average rating of “Buy” and an average target price of $11.33.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Soleus Capital Management LP increased its stake in Edap Tms shares by 6.5% during the fourth quarter. Soleus Capital Management LP now owns 3,148,609 shares of the medical equipment supplier valued at $18,860,000 after buying an additional 192,242 shares last quarter. Morgan Stanley increased its stake in Edap Tms shares by 92.2% during the 3rd quarter. Morgan Stanley now owns 1,497,285 shares of the medical equipment supplier worth $9,553,000 after acquiring an additional 718,460 shares in the last quarter. Fosun International Ltd increased its stake in Edap Tms shares by 1.7% during the 4th quarter. Fosun International Ltd now owns 179,039 shares of the medical equipment supplier valued at $949,000 after buying an additional 3,000 shares last quarter. Orion Capital Management LLC increased its stake in Edap Tms shares by 12.9% during the 3rd quarter. Orion Capital Management LLC now owns 91,803 shares of the medical equipment supplier valued at $586,000 after buying an additional 10,500 shares last quarter. Finally, Bank of America Corp DE increased its stake in Edap Tms by 403.4% in the 2nd quarter. Bank of America Corp DE now owns 42,959 shares of the medical equipment supplier valued at $304,000 after acquiring 34,426 additional shares in the last quarter. Institutional investors and hedge funds hold 27.20% of the company’s shares.

EDAP stock opened at $7.40 on Tuesday. The company has a 50-day moving average of $7.01 and a 200-day moving average of $6.29. Edap Tms has a fifty-two week minimum of $5.00 and a fifty-two week maximum of $9.88. The company has a quick ratio of 3.77, a current ratio of 4.34 and a debt ratio of 0.14.

Edap TMS Company Profile (Get an assessment)

EDAP TMS SA is a holding company which, through its subsidiary, deals with the development, production and marketing of minimally invasive medical devices for urological diseases. It operates through High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology.

Featured articles

Get a Free Copy of Zacks Research Report on Edap Tms (EDAP)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Edap Tms right now?

Before you consider Edap Tms, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market ripples…and Edap Tms didn’t make the list.

While Edap Tms currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here